Depression Treatment Guidelines

Introduction to Depression Treatment

The American Academy of Family Physicians and the American College of Physicians recommend that second-generation antidepressants (SSRIs/SNRIs) remain first-line treatment for depression, with L-methylfolate reserved only as adjunctive therapy in patients with inadequate response to antidepressants 1, 2
Embrace HR is not mentioned in any major depression treatment guidelines or research literature, making evidence-based recommendations impossible 1, 2, 3

All second-generation antidepressants (SSRIs and SNRIs) show equivalent efficacy for initial treatment, with medication choice based on side effect profiles, cost, and patient preference 1, 2
Preferred SSRIs include sertraline, escitalopram, citalopram, fluoxetine, and paroxetine 1, 4
38% of patients do not achieve treatment response during 6-12 weeks of SSRI treatment, and 54% do not achieve remission 5, 4

After adequate trial of first-line antidepressant (6-8 weeks at therapeutic doses) with inadequate response, consider switching to another SSRI or SNRI, or adding evidence-based psychotherapy (CBT or interpersonal therapy) 4, 5, 2
L-methylfolate 15 mg/day may be considered as adjunctive therapy in patients with SSRI-resistant depression and biomarkers of inflammation or metabolic disorders 4

Continue antidepressant therapy for 4-9 months after satisfactory response for first-episode depression 1, 4
Patients with recurrent depression require maintenance treatment ≥1 year to reduce relapse risk 1, 4
Meta-analysis of 31 trials supports continuation therapy to prevent relapse 5